Denali Therapeutics (DNLI) AI Stock Analysis

• Market Cap: $3.26B
• Dividend Yield: N/A
• Average Volume (3M): 1.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: N/A
• EPS Growth: -5.30%
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.73
• Shares Outstanding: 158,591,490
• 10 Day Avg. Volume: 1,558,975
• 30 Day Avg. Volume: 1,606,136
• PEG Ratio: -0.36
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.86
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.08K
• Enterprise Value/Ebitda: -5.83
• 1Y Price Target: $33.10
• Price Target Upside: 59.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -2.66
• Revenue Forecast (FY): $58.61M

• Rating: 55 Neutral
• Price Target: $22.00 ▲(6.28% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak financial performance (widening losses, zero revenue in 2024–2025, and ongoing cash burn). This is partly offset by strong technical momentum (price above key moving averages with positive MACD) and constructive corporate events that improve funding and highlight meaningful upcoming regulatory/clinical milestones, while valuation remains constrained by loss-making results and no dividend.

Positive Factors

Strong liquidity and low leverage

Material cash and recent financing actions provide a multi-quarter runway to advance pivotal trials and prepare commercial readiness for tividenofusp alfa. Low leverage further preserves flexibility, lowering near-term default risk and enabling program continuity independent of immediate product revenue.

TransportVehicle platform and broad CNS pipeline

A proprietary blood-brain-barrier TransportVehicle platform is a durable competitive advantage that addresses a core CNS delivery constraint. Platform applicability across Alzheimer’s, Pompe, LSDs and other CNS programs supports potential multi-asset value creation and sustained R&D productivity over multiple years.

Non-dilutive royalty funding while retaining rights

A $275M royalty funding deal provides substantial near-term capital without ceding commercial rights, aligning incentives for future sales. This structure reduces immediate dilution, supports late-stage development and potential launch costs, and preserves long-term upside from successful commercialization.

Negative Factors

Widening operating losses and cash burn

Rapidly expanding net losses and growing operating cash outflows materially increase financing needs and strategic risk. Sustained high burn narrows the window for clinical success or commercialization to restore profitability, raising the probability of future dilution or program reprioritization if milestones are delayed.

Zero product revenue in 2024–2025

Absence of recurring product sales makes cash flow dependent on one-time payments, milestone triggers and financings. This creates structural volatility: business continuity and funding hinge on binary regulatory and trial outcomes, limiting visibility into sustainable operating performance over the medium term.

Equity erosion and deeply negative returns on equity

Declining shareholders' equity and very negative ROE reflect ongoing capital consumption and poor returns on invested capital. Over time this weakens financial resilience, raises governance and capital allocation scrutiny, and increases dependence on external funding to sustain R&D and commercialization plans.

Denali Therapeutics Business Overview & Revenue Model

Company Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

How the Company Makes Money

Denali Therapeutics generates revenue primarily through collaborations and licensing agreements with other pharmaceutical companies. These partnerships often involve milestone payments and royalties from the commercialization of co-developed products. Additionally, Denali may receive funding from research grants and government contracts to support its R&D activities. The company focuses on advancing its drug candidates through clinical trials, aiming for regulatory approval and subsequent market entry to drive future revenue growth. Key partnerships with industry leaders help bolster its financial position and expand its development capabilities.

Denali Therapeutics Financial Statement Overview

Summary

Overall fundamentals are pressured by widening losses, inconsistent/absent revenue in 2024–2025, and sustained negative operating/free cash flow (continued cash burn). The balance sheet is a partial offset with low leverage, but equity erosion and deeply negative returns reflect ongoing capital consumption risk.

Income Statement

Operating performance has materially weakened versus 2020 profitability (net income of ~$71M in 2020 vs. losses of ~$145M in 2023, ~$423M in 2024, and ~$513M in 2025). Revenue has become inconsistent and recently absent (Total Revenue of $0 in 2024–2025 after $331M in 2023), which limits visibility and raises reliance on non-recurring sources. Losses are expanding (EBIT down to about -$555M in 2025), and margin metrics for 2024–2025 are not meaningful given zero revenue, underscoring a high-cost structure relative to current commercialization scale.

Balance Sheet

The balance sheet is a relative strength: leverage is low with debt-to-equity consistently modest (~0.03–0.07 across 2020–2025), providing financial flexibility. However, equity has declined from ~$1.23B (2024) to ~$1.01B (2025) alongside persistent losses, and returns on equity are deeply negative in recent years (about -51% in 2025), highlighting ongoing capital consumption risk if profitability does not improve.

Cash Flow

Cash generation is weak and deteriorating versus 2020: operating cash flow shifted from +~$416M (2020) to sustained outflows of roughly -$212M to -$413M (2021–2025). Free cash flow is consistently negative (about -$220M in 2021 to -$422M in 2025), indicating continued cash burn to fund operations and development. While free cash flow has generally tracked net income directionally (free cash flow roughly similar to net loss), the magnitude of ongoing burn increases financing dependence over time.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	330.53M	108.46M	48.66M
Gross Profit	-11.18M	0.00	330.53M	108.46M	48.66M
EBITDA	-497.63M	-492.89M	-179.97M	-330.36M	-287.16M
Net Income	-512.54M	-422.77M	-145.22M	-325.99M	-290.58M
Balance Sheet
Total Assets	1.14B	1.37B	1.15B	1.46B	1.40B
Cash, Cash Equivalents and Short-Term Investments	867.88M	832.33M	1.03B	1.34B	865.41M
Total Debt	42.29M	48.71M	52.24M	60.35M	64.01M
Total Liabilities	131.09M	144.50M	122.96M	417.81M	441.87M
Stockholders Equity	1.01B	1.23B	1.03B	1.04B	962.29M
Cash Flow
Free Cash Flow	-422.10M	-363.61M	-370.93M	-262.55M	-219.89M
Operating Cash Flow	-412.60M	-347.69M	-357.99M	-244.72M	-211.39M
Investing Cash Flow	255.28M	-88.76M	249.31M	-141.39M	-21.63M
Financing Cash Flow	189.22M	484.30M	17.82M	310.67M	19.35M

Denali Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNLI, the sentiment is Positive. The current price of 20.7 is above the 20-day moving average (MA) of 20.56, above the 50-day MA of 19.79, and above the 200-day MA of 16.50, indicating a bullish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 50.68 is Neutral, neither overbought nor oversold. The STOCH value of 69.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNLI.

Denali Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	63 Neutral	$2.82B	-228.91	-10.26%	―	129.21%	80.35%
CELC	56 Neutral	$5.29B	-12.63	-179.00%	―	―	-40.75%
DNLI	55 Neutral	$3.26B	-5.65	-50.13%	―	―	-5.30%
BEAM	54 Neutral	$2.56B	2.92	-7.31%	―	-84.07%	-157.71%
AGIO	52 Neutral	$1.63B	-3.82	-31.07%	―	36.26%	-158.98%
IDYA	52 Neutral	$2.88B	―	-11.10%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Denali Therapeutics Corporate Events

Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision

On January 6, 2026, Denali Therapeutics outlined its key priorities and expected milestones for 2026, positioning the year as a pivotal period as it prepares for a potential U.S. accelerated approval and commercial launch of tividenofusp alfa for Hunter syndrome, with an FDA decision due by April 5, 2026 and confirmatory data expected from the ongoing global Phase 2/3 COMPASS trial. The company also highlighted an anticipated wave of clinical readouts across its portfolio, including initial Phase 1/2 data for DNL126 in Sanfilippo syndrome Type A, patient data from the TAK-594/DNL593 frontotemporal dementia program, Phase 2b LUMA results for the LRRK2 Parkinson’s candidate BIIB122, and Phase 2 data for Sanofi-licensed eclitasertib in ulcerative colitis, alongside the initiation of first-in-human trials for multiple TV-enabled Alzheimer’s and Pompe disease therapies. Supported by roughly $873 million in cash and securities as of September 30, 2025, plus proceeds from a late-2025 equity raise and a royalty funding deal tied to future tividenofusp alfa sales, Denali signaled it has the capital to advance its clinical and commercial ambitions while reinforcing its strategy to establish leadership in transferrin receptor-enabled, blood-brain-barrier-crossing therapeutics.

The most recent analyst rating on (DNLI) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.

Denali Therapeutics Announces $200M Public Offering

On December 9, 2025, Denali Therapeutics entered into an underwriting agreement with major financial institutions for a public offering of its common stock and pre-funded warrants, aiming to raise approximately $200 million, potentially increasing to $230 million if additional shares are purchased. The offering is set to close on December 11, 2025, and is expected to strengthen Denali’s financial position, enhancing its ability to advance its therapeutic candidates and potentially impacting its market positioning in the biotechnology industry.

The most recent analyst rating on (DNLI) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.

Denali Therapeutics Secures $275M Royalty Funding Deal

On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty funding agreement with Royalty Pharma, which is contingent upon FDA approval of Denali’s investigational therapy, tividenofusp alfa, for Hunter syndrome. This agreement allows Denali to retain worldwide development and commercialization rights while providing Royalty Pharma a 9.25% royalty on future net sales, positioning Denali to advance its development programs and potentially transform treatment for Hunter syndrome.

The most recent analyst rating on (DNLI) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.

Denali Therapeutics Hosts Investor Day, Updates Pipeline

On December 4, 2025, Denali Therapeutics held its Investor Day, updating stakeholders on its development programs and future milestones. Key highlights include the ongoing FDA review of tividenofusp alfa for Hunter Syndrome, expected to conclude by April 2026, and the progression of other pipeline projects like DNL126 for Sanfilippo Syndrome and TAK-594 for Frontotemporal Dementia. The company anticipates minimal delays in its Pompe Disease program due to FDA requests for protocol amendments. These developments underscore Denali’s strategic focus on advancing its pipeline and preparing for potential commercial launches in 2026 and 2027.

The most recent analyst rating on (DNLI) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.